NLS Agreement

Orion Corporation has signed a European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone, a GABAA receptor modulator being investigated in multiple rare seizure disorders. Under the terms of the agreement, Orion will have the right to sell and market ganaxolone in Europe. Orion has made an upfront payment of EUR 25 million to Marinus as a signing fee. Marinus is also […]

Ipsen and IRLAB have signed a licensing agreement, providing Ipsen exclusive worldwide development and commercial rights to mesdopetam, a novel dopamine D3-receptor antagonist. “We are excited to enter this licensing agreement with IRLAB. By working in partnership, we aim to bring investigational mesdopetam to people living with Parkinson’s disease experiencing levodopa-induced dyskinesia,” says Howard Mayer, […]

The company has Sold its First NEOLA System to Tyndall National Institute at University College Cork to be used for a large study on newborn infants within the Irish Centre for Maternal and Child Health Research in Ireland. Tyndall National Institute at University College Cork in Ireland (UCC) will aquire a NEOLA system from GPX […]

Heartseed Inc. and Novo Nordisk A/S have entered into an exclusive worldwide collaboration and license agreement for development, manufacturing and commercialization of Heartseed’s HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure. “Through this […]

Sigrid Therapeutics has signed a collaboration agreement with the Japanese company AGC Si-Tech. “Discussions with AGC have been underway for years, and we’re very satisfied that we’ve now landed an agreement and managed to scale up manufacturing of SiPore15,” says Sana Alajmovic, CEO, Sigrid Therapeutics. Increased interest in the market While there are no approved […]

FrostPharma has entered an agreement with STEROP, bringing 5 additional products to the current FrostPharma portfolio. The deal encompasses commercial rights, including distribution and market authorization rights for the included products, states the company in a press release. “FrostPharma has showed a very strong development since the start in 2017 and we have continuously reinvested […]